ERBB3 and non-small cell lung carcinoma: Similarly, high levels of ERBB3 expression and activation of bypass signalling pathways were observed in EML4-ALK+positive NSCLC cells treated with either 1st or 2nd generation ALK-TKI such as crizotinib, ceritinib and alectinib [27, 28].